NYSE:NUVB Nuvation Bio Q4 2023 Earnings Report $2.15 -0.05 (-2.09%) Closing price 07/14/2025 03:59 PM EasternExtended Trading$2.13 -0.02 (-1.11%) As of 07:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Nuvation Bio EPS ResultsActual EPS-$0.06Consensus EPS -$0.10Beat/MissBeat by +$0.04One Year Ago EPSN/ANuvation Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANuvation Bio Announcement DetailsQuarterQ4 2023Date2/29/2024TimeN/AConference Call DateThursday, February 29, 2024Conference Call Time4:00PM ETUpcoming EarningsNuvation Bio's Q2 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Nuvation Bio Earnings HeadlinesAll You Need to Know About Nuvation Bio (NUVB) Rating Upgrade ... - NasdaqJuly 11, 2025 | nasdaq.comAnalysts Set Nuvation Bio Inc. (NYSE:NUVB) PT at $7.17July 10, 2025 | americanbankingnews.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.July 15 at 2:00 AM | Crypto 101 Media (Ad)Nuvation Bio Inc. (NUVB) latest stock news and headlines - Yahoo FinanceJuly 2, 2025 | uk.finance.yahoo.comJMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch PlansJune 29, 2025 | msn.comRBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy RatingJune 24, 2025 | msn.comSee More Nuvation Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email. Email Address About Nuvation BioNuvation Bio (NYSE:NUVB) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies for patients with advanced cancers. The company leverages an integrated drug discovery platform to identify and optimize small molecule and biologic candidates across a range of hematological malignancies and solid tumors. Nuvation Bio’s scientific team employs structure-based design, translational research and patient-centric clinical trial strategies to accelerate the path from target validation to regulatory submission. The company’s pipeline comprises multiple programs in Phase 1 and Phase 2 studies, each designed to address cancers with high unmet medical need. Nuvation Bio advances both single-agent and combination approaches, collaborating with academic institutions and contract research organizations to evaluate safety, pharmacokinetics and preliminary efficacy. Its lead programs target kinase inhibitors, immuno-oncology pathways and novel mechanisms of action that may overcome resistance observed with existing therapies. Founded in 2016 under the name Nuvation Pharmaceuticals and rebranded as Nuvation Bio in 2022, the company has assembled a leadership team with deep expertise in oncology drug development, regulatory affairs and commercial strategy. This team has guided Nuvation Bio through strategic financing rounds, an initial public offering on the New York Stock Exchange and the establishment of global research partnerships, positioning the company for sustained growth. Headquartered in Princeton, New Jersey, Nuvation Bio operates research and development facilities across North America and Europe. The company’s multidisciplinary workforce collaborates closely with patient advocacy groups, clinicians and regulatory authorities to design trials that reflect real-world patient populations. Nuvation Bio remains committed to advancing transformative therapies that improve outcomes for cancer patients worldwide.Written by Jeffrey Neal JohnsonView Nuvation Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings ASML (7/16/2025)Kinder Morgan (7/16/2025)U.S. Bancorp (7/16/2025)Bank of America (7/16/2025)Prologis (7/16/2025)Morgan Stanley (7/16/2025)Johnson & Johnson (7/16/2025)The PNC Financial Services Group (7/16/2025)Progressive (7/16/2025)The Goldman Sachs Group (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
